Metabolic Syndrome and Obesity

Primary mechanism — chronic positive energy balance

• Obesogenic energy surplus: Caloric intake exceeding expenditure expands visceral adipocytes beyond their safe storage capacity, triggering the adipocyte dysfunction and free fatty acid spillover described above. This accounts for the overwhelming majority of cases; secondary causes are the exception examiners plant deliberately.
• Gut–brain and sleep axis: Short sleep duration and untreated obstructive sleep apnea raise ghrelin, lower leptin signaling efficacy, and increase sympathetic tone and cortisol — a bidirectional loop with weight gain.

Secondary/endocrine causes (screen when the stem gives a clue)

• Cushing syndrome: cortisol drives visceral lipogenesis plus hepatic gluconeogenesis — look for purple striae, proximal myopathy, easy bruising.
• Hypothyroidism: reduced resting energy expenditure; weight gain is usually modest and fluid-predominant.
• PCOS: hyperandrogenism and insulin resistance are mutually reinforcing; the Endocrine Society recommends dysglycemia screening in all women with PCOS.
• Hypothalamic injury (craniopharyngioma, surgery, radiation) and monogenic/syndromic obesity (MC4R mutation, leptin receptor defects, Prader–Willi with hyperphagia and hypotonia).
• Lipodystrophies (congenital or HIV/antiretroviral-associated): severe insulin resistance and hypertriglyceridemia with little or no subcutaneous fat — the exception proving that fat location, not mass, drives the syndrome.

Drug-induced

• Second-generation antipsychotics (olanzapine, clozapine), glucocorticoids, insulin and sulfonylureas, thiazolidinediones, valproate, mirtazapine, and protease inhibitors.

Non-modifiable risk factors

• Advancing age; postmenopausal status in women (loss of estrogen shifts fat to the visceral depot); family history of type 2 diabetes; South Asian, Hispanic, and East Asian ancestry, for which the International Diabetes Federation applies lower ethnicity-specific waist thresholds; low birth weight with rapid catch-up growth (thrifty phenotype).

Modifiable risk factors

• Sedentary behavior (reduced GLUT4-mediated, insulin-independent muscle glucose uptake), diets high in added sugars and refined carbohydrate, sugar-sweetened beverages, excess alcohol, smoking (worsens insulin resistance despite lower BMI), untreated OSA, and food-insecure or low-access environments. The USPSTF frames these as the targets of intensive behavioral counseling for adults with BMI ≥30 kg/m².

• Adipose tissue dysfunction and insulin resistance: Visceral (central) obesity produces excessive free fatty acids and pro-inflammatory cytokines (TNF-α, IL-6, CRP) that impair insulin signaling via serine kinase activation on IRS-1, blocking phosphorylation of PI3K and downstream glucose uptake. Adiponectin (anti-inflammatory, insulin-sensitizing hormone) is paradoxically decreased in obesity despite higher adipose mass, further worsening insulin sensitivity.

• Lipid accumulation and ectopic fat deposition: Excess dietary energy stored as triglycerides in non-adipose tissues (liver, muscle, heart) creates lipotoxicity; diacylglycerols and ceramides accumulate intracellularly and activate PKC and stress pathways that suppress insulin signaling. Hepatic steatosis drives nonalcoholic fatty liver disease (NAFLD) and impairs hepatic insulin clearance.

• Chronic low-grade inflammation: Obesity creates a pro-inflammatory state through toll-like receptor (TLR) activation by free fatty acids, recruitment of macrophages into adipose tissue, and increased circulating endotoxin from dysbiotic gut microbiota. This systemic inflammation contributes to endothelial dysfunction, atherosclerosis acceleration, and β-cell dysfunction.

• Hyperinsulinemia and progressive β-cell exhaustion: Insulin resistance necessitates compensatory hyperinsulinemia initially, but chronic overstimulation of pancreatic β-cells leads to amyloid deposition, mitochondrial dysfunction, and eventual relative insulin deficiency, transitioning to type 2 diabetes.

• Hormonal dysregulation: Decreased adiponectin, increased leptin with leptin resistance, elevated angiotensinogen (renin-angiotensin system activation), increased cortisol metabolism in visceral fat, and altered sex hormone metabolism (decreased SHBG, altered estrogen) contribute to hypertension, dyslipidemia, and metabolic dysfunction.

• Endothelial dysfunction: Impaired nitric oxide availability due to increased ADMA (asymmetric dimethylarginine) and oxidative stress, combined with vascular inflammation, increases vascular stiffness and promotes atherosclerosis and hypertension.

• Central/abdominal obesity: Increased waist circumference (hallmark feature)—waist >40 inches in men or >35 inches in women is diagnostic criterion. Patients often report progressive weight gain despite unchanged dietary habits, difficulty losing weight, and frustration with previous diet attempts. The distribution (rather than total BMI) best predicts metabolic complications.

• Hypertension: Often mild to moderate (140-160/85-100 mmHg initially), resistant to monotherapy, and developing at relatively younger ages. May be asymptomatic or present with headaches, dyspnea on exertion, or incidental findings on screening.

• Dyslipidemia pattern: Elevated triglycerides (>150 mg/dL), low HDL-cholesterol (<40 mg/dL men, <50 mg/dL women), and elevated small, dense LDL particles (even if total LDL is normal)—this pattern is highly characteristic and different from primary hypercholesterolemia.

• Glucose abnormalities: Range from impaired fasting glucose (100-125 mg/dL) to impaired glucose tolerance (2-hour postprandial 140-199 mg/dL) to frank type 2 diabetes. Patients may be asymptomatic during prediabetic stages or report polyuria, polydipsia, and fatigue once diabetes develops.

• Metabolic manifestations: Acanthosis nigricans (dark, velvety skin thickening in neck/axillae) is a classic skin marker of severe insulin resistance; hirsutism and irregular menses in women due to hyperandrogenism; skin tags; easy bruising and impaired wound healing.

• Cardiovascular signs: Early signs of atherosclerosis including carotid bruits, diminished peripheral pulses, or claudication; physical exam may reveal xanthomas if severe dyslipidemia coexists.

• Sleep abnormalities: Obstructive sleep apnea (OSA) present in >50% of obese patients with metabolic syndrome—manifests as daytime somnolence, witnessed apneas, loud snoring, and morning headaches.

• IDF/WHO Metabolic Syndrome Criteria (most commonly used): Central obesity (waist circumference ≥94 cm men or ≥80 cm women) PLUS any 2 of the following: (1) elevated triglycerides ≥150 mg/dL or on lipid-lowering therapy, (2) reduced HDL <40 mg/dL (men) or <50 mg/dL (women) or on therapy, (3) elevated blood pressure ≥130/85 mmHg or on antihypertensive therapy, (4) elevated fasting glucose ≥100 mg/dL or type 2 diabetes. The NCEP ATP III criteria use similar thresholds with slightly higher waist cutoffs (102 cm men, 88 cm women).

• Laboratory assessment: Obtain fasting lipid panel, fasting glucose, and calculated HOMA-IR (homeostatic model assessment for insulin resistance: fasting insulin × fasting glucose / 405) to quantify insulin resistance; HbA1c to assess 3-month glycemic control; liver function tests and GGT to screen for NAFLD; uric acid (often elevated); and high-sensitivity CRP for inflammation assessment.

• Imaging and additional screening: Abdominal ultrasound or CT to assess visceral adiposity and screen for NAFLD (though ultrasound lacks sensitivity); consider sleep study if OSA suspected (STOP-BANG questionnaire useful screening tool); EKG and stress testing for cardiovascular risk stratification in older or symptomatic patients; carotid intima-media thickness as emerging risk marker.

• Differential diagnosis considerations: Exclude secondary causes of obesity (hypothyroidism, Cushing syndrome, polycystic ovary syndrome in women, genetic obesity syndromes); distinguish metabolic syndrome from primary dyslipidemia or hypertension alone; screen for depression and eating disorders.

• Lifestyle modification (first-line, essential foundation): Weight loss of 5-10% of body weight significantly improves all metabolic parameters and should be attempted before or concurrent with pharmacotherapy. Mediterranean or DASH diet preferred; target 150 minutes/week moderate aerobic activity plus resistance training 2×/week. Dietary approaches: caloric restriction (500-750 kcal/day deficit), reduced refined carbohydrates and added sugars, increased fiber (25-30 g/day), limited sodium (<2.3 g/day for hypertension). Behavioral counseling and referral to registered dietitian essential for sustained adherence.

• Pharmacotherapy for hypertension: ACE inhibitors or ARBs are first-line (additional metabolic benefits—improve insulin sensitivity, reduce proteinuria if present). Target BP <130/80 mmHg. Add thiazide diuretics (chlorthalidone preferred over hydrochlorothiazide due to longer half-life) or calcium channel blockers as second-line. Avoid beta-blockers as monotherapy (may worsen insulin resistance and lipids) unless clear indication present (post-MI, heart failure).

• Dyslipidemia management: High-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) are first-line for LDL reduction and cardiovascular risk reduction regardless of metabolic syndrome status if 10-year ASCVD risk >7.5%. For elevated triglycerides with metabolic syndrome, add fibrates (fenofibrate 145 mg daily) or high-dose omega-3 fatty acids if triglyce

Complications of the disease

• Type 2 diabetes mellitus: β-cell exhaustion superimposed on insulin resistance; signaled by rising HbA1c or fasting glucose crossing into the diabetic range. ADA Standards of Care recommend ongoing screening in all patients with overweight/obesity plus a risk factor.
• Atherosclerotic cardiovascular disease: small dense LDL particles penetrate and are retained in the intima more readily than buoyant LDL; endothelial dysfunction accelerates plaque formation. Acute coronary syndrome and ischemic stroke are emergencies — new chest pain or focal deficit demands immediate ECG/imaging, not outpatient risk calculation.
• Hyperosmolar hyperglycemic state: profound osmotic diuresis without ketosis because residual insulin suppresses lipolysis; marked hyperglycemia, high serum osmolality, and altered mental status. Emergency.
• MASLD/NAFLD progressing to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma: AASLD guidance endorses noninvasive fibrosis risk stratification (FIB-4 as the initial step, then elastography) rather than reflex biopsy.
• Obstructive sleep apnea and obesity hypoventilation: signaled by daytime hypercapnia and secondary erythrocytosis; can precipitate pulmonary hypertension and cor pulmonale.
• Chronic kidney disease: glomerular hyperfiltration and albuminuria; KDIGO recommends annual urine albumin-to-creatinine ratio and eGFR in diabetes.
• Other: heart failure (including HFpEF), atrial fibrillation, gout from hyperuricemia, cholelithiasis, venous thromboembolism, osteoarthritis, and increased risk of endometrial, breast (postmenopausal), colorectal, and esophageal adenocarcinoma.

Complications of treatment

• Metformin: vitamin B12 malabsorption (macrocytosis, neuropathy); lactic acidosis in advanced renal or hepatic failure.
• SGLT2 inhibitors: genital mycotic infection, volume depletion, and euglycemic DKA — check ketones despite a near-normal glucose. Emergency.
• GLP-1 receptor agonists/dual agonists: nausea, delayed gastric emptying, gallstones with rapid weight loss, pancreatitis; contraindicated with personal/family history of medullary thyroid carcinoma or MEN2A/2B.
• Thiazides: hyperglycemia, hyperuricemia/gout, hyponatremia. Statins: myopathy, rare rhabdomyolysis, small increase in incident diabetes that does not outweigh ASCVD benefit (ACC/AHA).
• Bariatric surgery: early anastomotic leak — unexplained tachycardia is the most sensitive sign and is a surgical emergency; later internal hernia, dumping syndrome, and deficiencies of thiamine (Wernicke encephalopathy), iron, B12, calcium, and vitamin D.

• Waist circumference beats BMI: the stem that gives a "normal-weight" patient with a large waist, high triglycerides, and low HDL is still describing metabolic syndrome. Visceral fat, not total adiposity, drives the pathology — which is why lipodystrophy produces the same metabolic picture with almost no subcutaneous fat.
• **The buzzword is *acanthosis nigricans***: velvety hyperpigmentation of the neck and axillae with skin tags is the exam's shorthand for hyperinsulinemia. In an adult with new, rapidly progressive acanthosis nigricans and weight loss, think paraneoplastic gastric adenocarcinoma instead.
• The single best next step in a newly recognized case is almost always lifestyle intervention plus ASCVD risk assessment, not a new drug. ACC/AHA primary prevention guidance uses the pooled cohort equations to drive statin decisions; metabolic syndrome features function as risk enhancers, not as an automatic statin indication. Do not label the patient a "CHD risk equivalent" — that is retired ATP III language.
• The association examiners test most is metabolic syndrome ↔ MASLD/NAFLD: mildly elevated aminotransferases with AST:ALT <1 in a patient with central obesity, before cirrhosis flips the ratio. AASLD supports risk-stratifying fibrosis noninvasively first.
• The dyslipidemia is high triglycerides, low HDL, and small dense LDL — total LDL can be normal. A stem emphasizing markedly high LDL with tendon xanthomas is familial hypercholesterolemia, a different disease.
• Screen for OSA and for PCOS — both are commonly the reason the patient is in the office, and treating OSA does not by itself reverse insulin resistance.
• Common distractors: HOMA-IR and hs-CRP are useful concepts but are not diagnostic criteria; beta blockers are avoided as antihypertensive monotherapy here but are never withheld when post-MI or HFrEF indications exist; and in a hyperglycemic patient on an SGLT2 inhibitor, a normal glucose does not exclude euglycemic DKA.